Navigation Links
Oncothyreon reports second quarter 2010 financial results
Date:8/5/2010

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported a net loss of $4.3 million or $0.17 per basic and diluted share for the quarter ended June 30, 2010, compared with a net loss of $6.3 million or $0.30 per basic and diluted share for the comparable period in 2009. Oncothyreon also reported a net loss of $5.1 million or $0.20 per basic and diluted share for the six months ended June 30, 2010, compared with a net loss of $8.8 million or $0.43 per basic and diluted share for the six months ended June 30, 2009. The decrease in net loss for the three and six months ended June 30, 2010 compared to the prior year periods was primarily attributable to a decrease in expense related to the change in fair value of warrant liability partially offset by increases in research and development and general and administrative expenses.

Research and development expenses increased to $2.8 million in the second quarter of 2010 from $2.0 million in the second quarter of 2009, and to $5.3 million for the first six months of 2010 from $2.7 million for the first six months of 2009, reflecting increased development and manufacturing activity for Oncothyreon's product candidates PX-866 and ONT-10. General and administrative expenses increased to
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces second quarter 2010 financial results conference call
2. Oncothyreon announces presentations at upcoming investor conferences in June
3. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
4. Oncothyreon reports full year and fourth quarter 2009 financial results
5. Oncothyreon reports first quarter 2010 financial results
6. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
7. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
8. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. Oncothyreon announces webcast of third quarter 2009 financial results conference call
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015  Cypher Genomics, Inc., a ... with Celgene Corporation to apply Cypher,s Coral TM ... associate with patient response to innovative medicines. The ... help accelerate patient access to the right medicine ... research and development and potentially inform new companion ...
(Date:5/20/2015)... TRIANGLE PARK, North Carolina , ... weltweit führende Unternehmen für klinische Logistik ... Finanzergebnisse für das Geschäftsjahr 2014, das ... und eingereicht. Das Unternehmen hat die ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... , May 20, 2015  HOSTING, the ... announced that it is an official partner ... Executives (CHIME) Cooperative Members Services Program. This ... compliant, managed cloud services and best practices ... healthcare CIOs and service providers, enabling member ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The Pistoia ... that work together to lower barriers to innovation in ... Alliances. The Map of Alliances project will catalogue the ... the life sciences sector and investigate how these collaborative ... The Map of Alliances project will see the Pistoia ...
Breaking Biology Technology:Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3Pistoia Alliance Launches New Map of Alliances project 2
... BIO CONVENTION, CHICAGO, Illinois , ... announced that its breakthrough treatment for tuberculosis,(TB) will shortly ... unique combination of its novel therapeutic vaccine called RUTI(R),in ... nine months,to one month, which reduces side effects and ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that the U.S. ... New Drug Application (NDA) for Esbriet™ (pirfenidone) for the treatment of patients ... , , ... issued by the FDA,s Center for Drug Evaluation and Research when the ...
... SAN MARINO, Calif. , May 4 ... genetic medicine, reports the publication of three major publications in ... Rexin-G, A Targeted Genetic Medicine for ... 2010) documents the development of Rexin-G : a tumor-targeted ...
Cached Biology Technology:Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 2Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 2InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 3InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 4InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application 5Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy 2Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy 3
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... Arbor, Mich. Patients with irritable bowel syndrome are ... or inflammatory bowel diseases than healthy people undergoing colonoscopies, ... Journal of Gastroenterology . "Patients and doctors get ... says William D. Chey, M.D., professor of Internal Medicine ...
... MADISON, WI, MARCH 8, 2010--Polycyclic aromatic hydrocarbons (PAHs) ... and oil. They are also produced as by-products of ... PAHs can cause cancer and other health effects. Because ... their levels are high enough to be a concern ...
... plays a crucial rule in the positioning and growth of limbs, ... the embryos of developing mice the layer of cells that ... hedgehog describes both a gene and the protein it produces in ... birth defects. It was thought to be exclusively present in ...
Cached Biology News:Patients with Irritable Bowel Syndrome not more likely to develop polyps, colon cancer 2Sources of pollution in waterways 2Sonic hedgehog gene found in an unexpected place during limb development 2Sonic hedgehog gene found in an unexpected place during limb development 3
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: